CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to understand the genetic and transcriptomic factors driving intra-tumour immune heterogeneity in non-small cell lung cancer. By developing personalized organoid models and co-culturing them with T-cells, the project seeks to identify mechanisms of resistance to immune checkpoint therapy.
Immune checkpoint blockade (ICB) has revolutionised treatment of patients with non-small cell lung cancer (NSCLC), but is effective in only ~20% of patients.
Anti-tumour immunity is highly heterogeneous within tumours, and intra-tumour heterogeneity (ITH) is a major driver for treatment resistance.
However, the mechanistic basis of intra-tumour immune heterogeneity (ITIH) is unclear, largely due to the absence of appropriate functional models.
Here, I aim to identify the genetic or transcriptomi…
THE FRANCIS CRICK INSTITUTE LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
